

FOR IMMEDIATE RELEASE

TSX VENTURE: HTL



**HAMILTON THORNE TO PRESENT AT THE 2016
BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE**

BEVERLY, MA and TORONTO, Ontario – April 28, 2016 – Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of precision laser devices and advanced image analysis systems for the ART (Assisted Reproductive Technologies), regenerative medicine and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne will present at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on May 3, 2016 at 3:00 p.m. Eastern Time.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in Canadian healthcare companies. Attendees will have an opportunity to obtain corporate updates from presenting companies and participate in 1-on-1 meetings with company management.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems that reduce cost, increase productivity, improve results and enable breakthroughs in ART (Assisted Reproductive Technologies), regenerative medicine and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Novartis, Pfizer, and Dow Chemical.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com

Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com